Yinchenhao Decoction Mitigates Cholestatic Liver Injury in Mice via Gut Microbiota Regulation and Activation of FXR-FGF15 Pathway
Pharmaceuticals · 20.06.2025 · 18 (7) · 932
DOI: 10.3390/ph18070932 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 20.06.2025. Verfasst von Weiwei Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, the 2024 Shanghai Public Health Research Special Project.
Abstract (Originalsprache)
Objective
Yinchenhao decoction (YCHD), a classical herbal formula comprising Artemisia capillaris, Gardenia jasminoides, and Rheum palmatum, has been clinically used for over 1000 years to treat cholestasis. However, its mechanism of action remains undefined. This study aimed to elucidate YCHD’s therapeutic mechanisms against cholestasis, with a focus on the gut microbiota-mediated regulation of the farnesoid X receptor (FXR)–fibroblast growth factor 15 (FGF15) pathway.
Methods
An alpha-naphthyl isothiocyanate (ANIT)-induced cholestasis mouse model was established. Mice received YCHD (3/9 g/kg) for 7 days. 16S rRNA sequencing, targeted LC/MS (bile acid (BA) quantification), untargeted GC/MS (fecal metabolite detection), qPCR/Western blot (FXR pathway analysis), fecal microbiota transplantation (FMT), and antibiotic depletion were employed to dissect the gut–liver axis interactions.
Results
YCHD alleviated cholestatic liver injury by reducing serum biomarkers, restoring BA homeostasis via FXR-FGF15 activation, and suppressing hepatic Cyp7a1-mediated BA synthesis. It remodeled gut microbiota, enriched FXR-activating secondary BAs (CDCA, DCA, CA), and restored the intestinal barrier integrity. Antibiotic cocktail abolished YCHD’s efficacy, while FMT from YCHD-treated mice enhanced its therapeutic effects, confirming microbiota dependency.
Conclusions
YCHD mitigates cholestasis through gut microbiota-driven FXR activation and direct hepatobiliary regulation. These findings bridge traditional medicine and modern pharmacology, highlighting microbiome modulation as a therapeutic strategy for cholestatic liver diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
- Medical Metabolomics Center, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- the 2024 Shanghai Public Health Research Special Project
- 2024 Shanghai Public Health Research Special Project
Zitieren
APA
Li, W., Huang, D., Luo, Z., Zhou, T., & Jin, Z. (2025). Yinchenhao Decoction Mitigates Cholestatic Liver Injury in Mice via Gut Microbiota Regulation and Activation of FXR-FGF15 Pathway. Pharmaceuticals, 18(7), 932. https://doi.org/10.3390/ph18070932
Vancouver
Li W, Huang D, Luo Z, Zhou T, Jin Z. Yinchenhao Decoction Mitigates Cholestatic Liver Injury in Mice via Gut Microbiota Regulation and Activation of FXR-FGF15 Pathway. Pharmaceuticals. 2025;18(7):932. doi:10.3390/ph18070932
BibTeX
@article{Li2025,
author = {Li, Weiwei and Huang, Doudou and Luo, Zichen and Zhou, Ting and Jin, Ziwen},
title = {Yinchenhao Decoction Mitigates Cholestatic Liver Injury in Mice via Gut Microbiota Regulation and Activation of FXR-FGF15 Pathway},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {7},
pages = {932},
doi = {10.3390/ph18070932}
}
EUVIMED